Envista Holdings Co. (NYSE:NVST) Receives $20.21 Consensus Target Price from Analysts

Envista Holdings Co. (NYSE:NVST) has been assigned an average rating of “Hold” from the fourteen analysts that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $20.21.

NVST has been the subject of several recent analyst reports. Wells Fargo & Company raised their target price on shares of Envista from $20.00 to $21.00 and gave the stock an “equal weight” rating in a report on Thursday, February 6th. Needham & Company LLC reiterated a “hold” rating on shares of Envista in a report on Thursday, February 6th. Piper Sandler raised their target price on shares of Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. Jefferies Financial Group raised their target price on shares of Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a report on Thursday, January 23rd. Finally, Morgan Stanley raised their price target on shares of Envista from $19.00 to $20.00 and gave the stock an “equal weight” rating in a report on Thursday, February 6th.

Envista Stock Performance

NYSE:NVST opened at $21.36 on Tuesday. Envista has a twelve month low of $15.15 and a twelve month high of $23.00. The company has a current ratio of 2.04, a quick ratio of 1.76 and a debt-to-equity ratio of 0.44. The company has a 50-day moving average of $20.15 and a 200-day moving average of $19.59. The firm has a market cap of $3.68 billion, a price-to-earnings ratio of -3.29, a price-to-earnings-growth ratio of 1.27 and a beta of 1.34.

Envista (NYSE:NVST) last announced its earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. Analysts forecast that Envista will post 1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Envista

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NVST. Mirae Asset Global Investments Co. Ltd. bought a new position in Envista during the third quarter valued at approximately $31,000. Huntington National Bank raised its position in Envista by 97.8% during the third quarter. Huntington National Bank now owns 1,919 shares of the company’s stock valued at $38,000 after acquiring an additional 949 shares in the last quarter. Venturi Wealth Management LLC raised its position in Envista by 528.4% during the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock valued at $38,000 after acquiring an additional 1,638 shares in the last quarter. Blue Trust Inc. raised its position in Envista by 69.7% during the third quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after acquiring an additional 804 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in Envista by 50.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock valued at $43,000 after acquiring an additional 728 shares in the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.